# EDGAR Filing Document

**Accession Number:** 0001087294
**File Stem:** 0001628280-23-001129
**Filing Date:** 2023-1
**Character Count:** 4952
**Document Hash:** 833fc18be231fcdb7fc42d32a8418bcd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-23-001129.hdr.sgml**: 20230117

**ACCESSION NUMBER**: 0001628280-23-001129

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230117

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20230117

**DATE AS OF CHANGE**: 20230117

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CUMBERLAND PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0001087294
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33637
- **FILM NUMBER:** 23532172

**BUSINESS ADDRESS:**
- **STREET 1:** 2525 WEST END AVENUE
- **STREET 2:** SUITE 950
- **CITY:** NASHVILLE,
- **STATE:** TN
- **ZIP:** 37203
- **BUSINESS PHONE:** 615-255-0068

**MAIL ADDRESS:**
- **STREET 1:** 2525 WEST END AVENUE
- **STREET 2:** SUITE 950
- **CITY:** NASHVILLE
- **STATE:** TN
- **ZIP:** 37203

?xml version="1.0" ? cpix-20230117

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

January 17, 2023 (January 14, 2023)

Date of Report (date of earliest event reported)

**CUMBERLAND PHARMACEUTICALS INC.** 

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Tennessee** | **001-33637** | **62-1765329** |
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

**1600 West End Avenue, Suite 1300 Nashville, Tennessee 37203**

**(Address of Principal Executive Offices)**

**(615) 255-0068** 

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered <br> <u>Common Stock, no par value</u> <u>CPIX</u> <u>NASDAQ Global Select Market</u>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On January 14, 2023, Cumberland Pharmaceuticals Inc. ("Cumberland" or the "Company") learned that Joey A. Jacobs, a member of Cumberland's Board of Directors, had passed away. Mr. Jacobs served as a member of the Company's Board of Directors since 2011. He was the Chairman of our Governance and Nominating Committee, as well as our Lead Independent Director.

Mr. Jacobs had over 45 years of experience in the healthcare industry. He was the former Chairman and Chief Executive Officer of Acadia Healthcare, a behavioral health company. Mr. Jacobs was also the former Chairman, President and Chief Executive Officer of Psychiatric Solutions, Inc. (PSI), which he co-founded in 1997 and grew into a $2 billion behavioral healthcare system before the company's sale to Universal Health Services in 2010. Prior to founding PSI, Mr. Jacobs spent 21 years at Hospital Corporation of America, or HCA, where he served in various capacities.

The Company's Board of Directors plans to meet and reassign Mr. Jacobs' responsibilities.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | Cumberland Pharmaceuticals Inc. | Cumberland Pharmaceuticals Inc. |
| Dated: January 17, 2023 | By: | */s/ John Hamm* |
|  |  | John Hamm |
|  |  | Chief Financial Officer |

---